| dc.contributor.author | Yilmaz, Rahmi | |
| dc.contributor.author | Akoglu, Hadim | |
| dc.contributor.author | Yirkpantur, Alper | |
| dc.contributor.author | Kilickap, Saadettin | |
| dc.contributor.author | Arici, Mustafa | |
| dc.contributor.author | Altun, Bulent | |
| dc.contributor.author | Aki, Tuncay | |
| dc.contributor.author | Erdem, Yunus | |
| dc.contributor.author | Yasavul, Unal | |
| dc.contributor.author | Turgan, Cetin | |
| dc.date.accessioned | 2019-12-10T11:10:05Z | |
| dc.date.available | 2019-12-10T11:10:05Z | |
| dc.date.issued | 2007 | |
| dc.identifier.issn | 0886-022X | |
| dc.identifier.uri | https://doi.org/10.1080/08860220601039528 | |
| dc.identifier.uri | http://hdl.handle.net/11655/14808 | |
| dc.description.abstract | Renal transplant recipients are susceptible to Kaposi's sarcoma (KS) because of treatment with immunosuppressive drugs. Sirolimus, a new immunosuppressive agent, has been successfully used for immune-suppression in kidney transplant recipients. Several studies have shown the potential role of sirolimus to inhibit progression of KS in kidney-transplant recipients. This report details a kidney-transplant recipient with cutaneous KS who had a complete remission in response to sirolimus therapy. | |
| dc.language.iso | en | |
| dc.publisher | Taylor & Francis Inc | |
| dc.relation.isversionof | 10.1080/08860220601039528 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Urology & Nephrology | |
| dc.title | A Novel Immunosuppressive Agent, Sirolimus, in the Treatment of Kaposi'S Sarcoma in a Renal Transplant Recipient | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.relation.journal | Renal Failure | |
| dc.contributor.department | İç Hastalıkları | |
| dc.identifier.volume | 29 | |
| dc.identifier.issue | 1 | |
| dc.identifier.startpage | 103 | |
| dc.identifier.endpage | 105 | |
| dc.description.index | WoS | |
| dc.description.index | Scopus | |
